Pharmacyclics Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PHARMACYCLICS LLC, and when can generic versions of PHARMACYCLICS LLC drugs launch?
PHARMACYCLICS LLC has three approved drugs.
There are forty-one US patents protecting PHARMACYCLICS LLC drugs.
There are three hundred and forty-five patent family members on PHARMACYCLICS LLC drugs in forty-five countries and thirty-four supplementary protection certificates in fifteen countries.
Summary for Pharmacyclics Llc
International Patents: | 345 |
US Patents: | 41 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 3 |
Patent Litigation for Pharmacyclics Llc: | See patent lawsuits for Pharmacyclics Llc |
Drugs and US Patents for Pharmacyclics Llc
Paragraph IV (Patent) Challenges for PHARMACYCLICS LLC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 140 mg and 560 mg | ➤ Subscribe | 2018-11-05 |
➤ Subscribe | Capsules | 70 mg | ➤ Subscribe | 2018-12-14 |
➤ Subscribe | Tablets | 280 mg and 420 mg | ➤ Subscribe | 2018-12-14 |
International Patents for Pharmacyclics Llc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 4115886 | ⤷ Try a Trial |
New Zealand | 789041 | ⤷ Try a Trial |
Australia | 2016226279 | ⤷ Try a Trial |
Poland | 2201840 | ⤷ Try a Trial |
Lithuania | 2530083 | ⤷ Try a Trial |
South Korea | 20130086957 | ⤷ Try a Trial |
South Korea | 101425248 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pharmacyclics Llc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2201840 | PA2015017,C2201840 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
2526934 | CA 2016 00056 | Denmark | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2016)3293 20160530 |
2201840 | 92692 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023 |
2201840 | C20150014 00145 | Estonia | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014 |
2526934 | 122016000093 | Germany | ⤷ Try a Trial | PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20160526 |
2526934 | 93321 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/14/945 - IMBRUVICA - IBRUTINIB |
2529621 | CA 2017 00012 | Denmark | ⤷ Try a Trial | PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.